Spearhead Capital Advisors’s Cardlytics CDLX Stock Holding History

Spearhead Capital Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-334	Closed	-$477K	–	191
2020 Q4	$477K	Buy	334 +6	+2%	+$6.4K	0.08%	101
2020 Q3	$232K	Buy	328 +24	+8%	+$17.4K	0.04%	164
2020 Q2	$213K	Buy	+304	New	+$176K	0.05%	152

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Spearhead Capital Advisors's CDLX Position: Q1 2021 in Review

Spearhead Capital Advisors sold out of Cardlytics (CDLX) in Q1 2021, closing a stake of 334 shares — an estimated $477K sold.

Spearhead Capital Advisors first reported a position in CDLX in Q2 2020 and held it in 3 quarters. The position peaked at $477K in Q4 2020. 204 funds tracked by Wall St. Rank hold CDLX as of Q1 2021.

Spearhead Capital Advisors reported no remaining Cardlytics position as of Q1 2021 after selling out during the quarter.
Spearhead Capital Advisors sold 334 Cardlytics shares in Q1 2021, an estimated $477K.
Spearhead Capital Advisors first reported a position in Cardlytics in Q2 2020 and held it in 3 quarters.
Spearhead Capital Advisors's Cardlytics position peaked at $477K in Q4 2020.
204 funds tracked by Wall St. Rank held Cardlytics as of Q1 2021.

Based on Spearhead Capital Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.